作为跨国企业在中国设立的第一个世界级生物制药生产基地，勃林格殷格翰中国生物制药自落成以来，就积极推动公司可持续发展战略在华落地。2015年以来，勃林格殷格翰中国生物制药两处厂址经绿色设计、建设后先后投入运营，并于2021年实现碳排放达峰（12,196吨）。此后，公司制定了完善的"碳中和"路线图，从能效升级、可再生能源转换、生产仓储与实验室流程优化，以及绿色文化与行为建设等方面做了全面的脱碳设计，历时近10年将碳排放中和为零。

勃林格殷格翰中国生物药业总经理臧雨果博士表示："勃林格殷格翰在中国生物制药行业率先达成国内外权威认证的碳中和目标，以实际行动应对和减缓气候变化，有力践行了勃林格2030年达成零碳目标的坚定承诺，我们深感自豪。作为全球生物制药行业绿色低碳发展的领军者，勃林格殷格翰将致力于推动公司运营中节能增效，通过数字化、智能化管理推进新质发展。我们也希望携手各界伙伴，积极探索产业链上下游的脱碳路径，持续赋能中国生物制药行业的创新生态。"

勃林格殷格翰中国生物制药基地的碳中和进程严格遵循公司的整体脱碳战略，依据科学碳目标倡议（SBTi）制定企业目标，覆盖碳排放数据采集、碳排放指标分解、场地碳管理、能源管理、绿证追踪、碳中和数据盘查及验证等等环节，均符合《温室气体核算体系》以及ISO 14064-1:2018《组织层面上对温室气体排放和清除的量化和报告的规范及指南》，真正做到了规划科学、实施精准、监管透明。

As the first world-class biopharmaceutical production base established by a multinational company in China, Boehringer Ingelheim China Biopharmaceutical has been actively promoting the company's sustainable development strategy in China since its establishment. Since 2015, Boehringer Ingelheim's two biopharmaceutical sites in China have been put into operation after green design and construction, and will achieve the peak carbon emissions (12,196 tons) in 2021. Since then, the company has developed a comprehensive "carbon neutral" roadmap, from energy efficiency upgrading, renewable energy conversion, production storage and laboratory process optimization, as well as green culture and behavior construction and other aspects of a comprehensive decarbonization design, which has lasted nearly 10 years to neutralize carbon emissions to zero.

Dr. Hugo Zang, General Manager of Boehringer Ingelheim China Biopharmaceutical, said: "We are proud that Boehringer Ingelheim has taken the lead in China's biopharmaceutical industry to achieve the carbon neutrality target certified by both domestic and international authorities, and has effectively implemented Boehringer's firm commitment to achieving zero carbon by 2030. As a global leader in the green and low-carbon development of the biopharmaceutical industry, Boehringer Ingelheim is committed to promoting energy conservation and efficiency in its operations and promoting new quality development through digital and intelligent management. We also hope to work with partners from all walks of life to actively explore the path of decarbonization of the upstream and downstream of the industrial chain, and continue to empower the innovation ecology of China's biopharmaceutical industry."

The carbon neutrality process of Boehringer Ingelheim China biopharmaceutical base strictly follows the company's overall decarbonization strategy, and sets corporate goals according to the Scientific Carbon Target Initiative (SBTi), covering carbon emission data collection, carbon emission index decomposition, site carbon management, energy management, green certificate tracking, carbon neutral data inventory and verification, etc. All are in line with the Greenhouse Gas Accounting System and ISO 14064-1:2018 "Norms and Guidelines for the Quantification and Reporting of Greenhouse Gas emissions and removals at the Organizational Level", and truly achieve scientific planning, accurate implementation and transparent supervision.